NCT06014580View on ClinicalTrials.gov

Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil

Active, not recruitingOBSERVATIONAL
Enrollment

276

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Endometrial Cancer
Interventions
OTHER

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Trial Locations (7)

60.430-230

ICC - Instituto do Câncer do Ceará, Fortaleza

29.308-065

Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO), Cachoeiro de Itapemirim

Unknown

Santa Casa de Misericórdia de Feira de Santana, Feira de Santana

79.002-061

Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo, Campo Grande

79.601-001

Instituto do Câncer Brasil - Unidade Três Lagoas, Três Lagoas

85.806-300

UOPECCAN - Hospital do Câncer de Cascavel, Cascavel

20.230-130

INCA - Instituto Nacional de Câncer, Rio de Janeiro

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Latin American Cooperative Oncology Group

OTHER

NCT06014580 - Molecular and Epidemiological Characteristics of Endometrial Cancer in Brazil | Biotech Hunter | Biotech Hunter